Everolimus and Octreotide for Patients with Recurrent Meningioma: Results from the Phase II CEVOREM Trial

authors

  • Graillon Thomas
  • Sanson Marc
  • Campello Chantal
  • Idbaih Ahmed
  • Peyre Matthieu
  • Peyrière Hadrien
  • Basset Noémie
  • Autran Didier
  • Kalamarides Michel
  • Roche Pierre-Hugues
  • Fuentes Stéphane
  • Tabouret Emeline
  • Barrie Maryline
  • Cohen Anita
  • Honoré Stéphane
  • Boucekine Mohamed
  • Baumstarck Karine
  • Figarella‑branger Dominique
  • Barlier Anne
  • Dufour Henry
  • Chinot Olivier Louis

abstract

Aggressive meningiomas that progress after surgery/radiotherapy represent an unmet medical need. Strong and constant expression of SSTR2A receptors and activation of the Pi3K/Akt/mTOR pathway have been demonstrated in meningiomas. The combination of everolimus, an mTOR inhibitor, and octreotide, a somatostatin agonist, has shown additive antitumor effect in vitro. The phase II CEVOREM trial investigated the efficacy of this combination on recurrent meningiomas.

more information